Generex Biotechnology Corp. (fka GNBTQ)

[DB9]

Expert Opin Biol Ther.
2009 Jan

CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37).
Mittendorf EA, Holmes JP, Murray JL, von Hofe E, Peoples GE.
University of Texas MD Anderson Cancer Center, Department of Surgical Oncology, Houston, TX 77030, USA. [e-mail]
http://www.ncbi.nlm.nih.gov/pubmed/19063694?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum


BACKGROUND: Early clinical trials of HER2/neu-derived peptide vaccines indicate that they may be useful for preventing recurrence in breast cancer patients rendered disease-free after standard-of-care therapy. An effective vaccination strategy will probably require stimulation of T helper (Th) cells. AE37 is an HER2/neu-derived peptide that has been modified to enhance antigen-specific stimulation of Th cells by linkage of the Ii-Key moiety of the MHC class II-associated invariant chain (Ii protein).
OBJECTIVE: To review the literature regarding the role of a Th response in immunotherapy with a focus on this novel HER2/neu-derived AE37 peptide.
RESULTS/CONCLUSION: Improved immuno-genicity of the AE37 Ii-key hybrid peptide has been demonstrated in animal models, ex vivo patient cells, and, most recently, in a Phase I clinical trial in breast cancer patients. Future clinical trials incorporating AE37 into a peptide vaccine strategy are warranted.

PMID: 19063694 [PubMed - indexed for MEDLINE